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Résumé en
anglais
CONTEXT: Germline mutations in the aryl hydrocarbon receptor interacting
protein gene (AIP) have been identified in young patients (age ≤30 years old) with
sporadic pituitary macroadenomas. Otherwise, there are few data concerning the
prevalence of multiple endocrine neoplasia type 1 (MEN1) mutations in such a
population.
OBJECTIVE: We assessed the prevalence of both AIP and MEN1 genetic
abnormalities (mutations and large gene deletions) in young patients (age ≤30
years old) diagnosed with sporadic and isolated macroadenoma, without
hypercalcemia and/or MEN1-associated lesions.
DESIGN: The entire coding sequences of AIP and MEN1 were screened for
mutations. In cases of negative sequencing screening, multiplex ligation-dependent
probe amplification was performed for the detection of large genetic deletions.
PATIENTS AND SETTINGS: One hundred and seventy-four patients from
endocrinology departments of 15 French University Hospital Centers were eligible
for this study.
RESULTS: Twenty-one out of 174 (12%) patients had AIP (n=15, 8.6%) or MEN1
(n=6, 3.4%) mutations. In pediatric patients (age ≤18 years old), AIP/MEN1
mutation frequency reached nearly 22% (n=10/46). AIPmut and MEN1mut were
identified in 8/79 (10.1%) and 1/79 (1.2%) somatotropinoma patients respectively;
they each accounted for 4/74 (5.4%) prolactinoma (PRL) patients with mutations.
Half of those patients (n=3/6) with gigantism displayed mutations in AIP.
Interestingly, 4/12 (33%) patients with non-secreting adenomas bore either AIP or
MEN1 mutations, whereas none of the eight corticotroph adenomas or the single
thyrotropinoma case had mutations. No large gene deletions were observed in
sequencing-negative patients.
CONCLUSION: Mutations in MEN1 can be of significance in young patients with
sporadic isolated pituitary macroadenomas, particularly PRL, and together with AIP,




Titre abrégé Eur. J. Endocrinol.
Identifiant












































Publié sur Okina (http://okina.univ-angers.fr)
